Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20371029 | 1.00 | ALDH1A1 (0.41) | ALDH1A1GAAL3MBTL1ATMCYP3A4 | |
| SCHEMBL14827501 | 0.91 | ALDH1A1 (0.39) | ALDH1A1GAAL3MBTL1ATMCYP3A4 | |
| SCHEMBL12734316 | 0.82 | GAA (0.35) | ALDH1A1GAAL3MBTL1ATMCYP3A4 | |
| SCHEMBL1104567 | 0.80 | ATM (0.40) | ALDH1A1GAAL3MBTL1ATMCYP3A4 | |
| SCHEMBL1104570 | 0.79 | ATM (0.39) | ALDH1A1GAAL3MBTL1ATMCYP3A4 | |
| SCHEMBL16358149 | 0.79 | ATM (0.39) | ALDH1A1GAAL3MBTL1ATMCYP3A4 | |
| SCHEMBL10188814 | 0.76 | CYP3A4 (0.39) | ALDH1A1GAAL3MBTL1ATMCYP3A4 | |
| SCHEMBL18356894 | 0.73 | MAPT (0.36) | ALDH1A1GAAPOLBMAPTTP53 | |
| SCHEMBL13325754 | 0.72 | ATM (0.39) | ALDH1A1ATMCYP3A4POLBMAPT | |
| SCHEMBL13743882 | 0.68 | ALDH1A1 (0.39) | ALDH1A1GAAL3MBTL1ATMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023861-B2 | Oligomer-conjugate complexes and their use | IONIS PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023861-B2 | Oligomer-conjugate complexes and their use | DCLRE1B, NT5C3B, PAICS | ALDH1A1 3027/4885GAA 809/4885L3MBTL1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.